| USA News Group - Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit nearly $310 billion by 2030, according to Allied Analytics. Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis. Last December, biotechs working on breast cancer treatments saw their shares soar. This year has continued that momentum, with multiple biotech companies driving progress in the fight against cancer, including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), BriaCell Therapeutics Corp. (NASDAQ:BCTX), Gilead Sciences, Inc. (NASDAQ:GILD), and Eli Lilly and Company (NYSE:LLY). Coming up between December 11-14, 2021, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) will give an update at the upcoming 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) on its Phase II Triple-Negative Breast Cancer Trial--known as the IRENE study, which is evaluating the company's flagship product pelareorep, an immunotherapeutic agent that turns "cold" tumors "hot", in combination with the anti-PD-1 checkpoint inhibitor, retifanlimab, from Incyte Corporation (NASDAQ:INCY). Accompanying the IRENE study, Oncolytics Biotech's pelareorep is being evaluated for multiple cancer types, of which the company recently updated the market on, including its AWARE-1 breast cancer study, BRACELET-1 breast cancer trial, a phase 1/2 GOBLET trial for treating gastrointenstinal cancer. "Over the past few months, we achieved key milestones that have advanced pelareorep's development programs and further highlighted the advantages of its broadly applicable mechanism of action," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech. "These milestones include the reporting of new clinical biomarker data from our AWARE-1 breast cancer study, which we are pleased to be announcing today. These data further demonstrate pelareorep's immunotherapeutic effects and its ability to synergize with checkpoint inhibition. It also indicates that changes in peripheral blood T cell populations may be predictive of patient response. This exciting finding could improve our chances of success in subsequent studies by allowing for early identification of patients most likely to benefit from pelareorep therapy. We are evaluating this hypothesis as part of our BRACELET-1 breast cancer trial, which is assessing the safety, efficacy, and pharmacodynamic effe cts of pelareorep with and without checkpoint inhibition to support the advancement of our lead program to a registrational study." So far there have been several potential suitors for pelareorep, including from Roche, Merck, Merck KGaA, Bristol-Myers Squibb, and Pfizer Inc., all of which make oncology drugs that are being evaluated in combination with pelareorep. Incyte Corporation (NASDAQ:INCY) will also be presenting at the ASH 2021 Meeting and Exposition, with numerous oral presentations highlighting data for tafasitamab, parsaclisib, ruxolitinib, pemigatinib, itacitinib and ponatinib to be highlighted during the Congress. "We are excited for the opportunity to present, along with our partners, more than 35 abstracts and share progress from Incyte's oncology portfolio at this year's ASH meeting," said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapeutics, Incyte. "The oral presentations, including new data from the CITADEL program evaluating parsaclisib in three types of lymphoma as well as results from the RE-MIND2 study of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, highlight the strength of our robust oncology portfolio and underscore our commitment to addressing urgent medical needs for people with cancer." BriaCell Therapeutics Corp. (NASDAQ:BCTX) recently announced that the Mary Crowley Cancer Research center in Dallas, TX is now actively screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of the biotech developer's lead candidate, Bria-IMTTM, also with Incyte's checkpoint inhibitors, retifanlimab and epacadostat. Leading the study as the clinical site's Principal Investigator is Dr. Minal Barve, the Executive Medical Director and Chief Medical Officer for Mary Crowley Cancer Research center and Board-Certified in medical oncology and internal medicine. "We are delighted to add Mary Crowley Cancer Research center with Dr. Barve as Principal Investigators to our team," stated Dr. Williams, BriaCell's President and CEO. "Dr. Barve's leading knowledge and experience in biological therapies and immunotherapies for cancer will be highly valuable to us. We look forward to working with her team in our advanced breast cancer clinical trial to accelerate patient recruitment." BriaCell had previously reported 12 months average overall survival in advanced breast cancer patients in its Phase I/IIa combination study, which also included 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors, compared with 7.2-9.8 months survival in historical comparison treatment studies. Among those, the top responder patient showed 21.4 months survival plus 100% resolution of 'eye-bulging' orbital tumor. Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) recently became one of the newest antibody-drug conjugates approved to treat metastatic triple-negative breast cancer in Europe. Marketed as a first-in-class antibody and topoisomerase inhibitor conjugate, Trodelvy is directed to the Trop-2 receptor, a protein that is overexpressed in several tumours including metastatic TNBC and is associated with poor survival and relapse. Trodelvy is already approved in multiple countries worldwide in second-line metastatic TNBC, including Australia, Canada, Great Britain and Switzerland as well as the USA where it's also approved for metastatic urothelial cancer. "At Gilead, we push boundaries to deliver transformative science and novel treatment options that address urgent medical needs," said Merdad Parsey (MD, PhD), Chief Medical Officer of Gilead. "We understand how difficult metastatic TNBC is to treat and we're proud that Trodelvy can now offer a second-line treatment option with the potential to bring longer life to people living with this aggressive disease." Following a decision by the UK's National Institute for Health and Care Excellence (NICE), adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) will now have access to Retsevmo (selpercatinib) from Eli Lilly and Company (NYSE:LLY), via the Cancer Drugs Fund (CDF) in England. Under the trade name Retsevmo, the targeted treatment option is recommended for use within the Cancer Drugs Fund as an option for treating RET fusion-positive advanced non-small-cell lunch cancer (NSCLC) in adults who need systemic therapy after immunotherapy, platinum-based chemotherapy for both. "The development of this targeted oral therapy is thanks to advances in our scientific understanding of the role of RET alterations," said Dr Jeff Yang, senior medical director, Northern Europe, Eli Lilly and Company. "I'm delighted by the news that NICE have chosen to recommend selpercatinib as the first targeted therapy for RET fusion-positive non-small cell lung cancer, offering new hope to people with this rare type of lung cancer." For more information please visit: https://usanewsgroup.com/2020/02/24/why-biotechnology-companies-are-so-important/ Article Source: USA News Grouphttps://USAnewsgroup.cominfo@usanewsgroup.com DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which c ould have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identifie d in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. |